scholarly journals Travoprost with sofZia® preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects

2014 ◽  
pp. 347 ◽  
Author(s):  
Shiro Mizoue ◽  
Tadashi Nakano ◽  
Nobuo Fuse ◽  
Aiko Iwase ◽  
Shun Mastumoto ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Side Effects ◽  
Normal Tension Glaucoma

Intraocular pressure measured by dynamic contour tonometer and ocular response analyzer in normal tension glaucoma

2009 ◽  
Vol 248 (1) ◽  
pp. 73-77 ◽  
Author(s):  
Tetsuya Morita ◽  
Nobuyuki Shoji ◽  
Kazutaka Kamiya ◽  
Mana Hagishima ◽  
Fusako Fujimura ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Normal Tension Glaucoma ◽  
Ocular Response Analyzer ◽  
Dynamic Contour Tonometer

scholarly journals Surgery for normal tension glaucoma. Target intraocular pressure and visual field progression

2009 ◽  
Vol 75 (S224) ◽  
pp. 43-44 ◽  
Author(s):  
L. Fontana ◽  
A. C. Viswanathan ◽  
D. Poinooswamy ◽  
R. A. Hitchings ◽  
L. Scullica
Keyword(s):  
Intraocular Pressure ◽  
Visual Field ◽  
Normal Tension Glaucoma ◽  
Visual Field Progression

Comparisons of Intraocular-Pressure- Lowering Efficacy and Side Effects of 2% Dorzolamide and 1% Brinzolamide

2001 ◽  
Vol 215 (3) ◽  
pp. 188-191 ◽  
Author(s):  
Gong Je Seong ◽  
Sung Chul Lee ◽  
Jong Hyuck Lee ◽  
Young Kwang Chu ◽  
Young Jae Hong
Keyword(s):  
Intraocular Pressure ◽  
Side Effects ◽  
Pressure Lowering

scholarly journals Effect of brimonidine on central corneal thickness in normal tension glaucoma patients

2019 ◽  
Vol 7 (6) ◽  
pp. 2216
Author(s):  
Neethu K. V. ◽  
Latha N. V. ◽  
Praveena K. K.
Keyword(s):  
Intraocular Pressure ◽  
Central Corneal Thickness ◽  
Corneal Thickness ◽  
Topical Administration ◽  
Normal Tension Glaucoma ◽  
Thickness Measurement ◽  
Applanation Tonometry ◽  
Time Period ◽  
Field Assessment ◽  
History Of

Background: Brimonidine is a potent ocular hypotensive agent widely used in glaucoma treatment. A reduction in central corneal thickness can lead to an underestimation of intraocular pressure by Goldmann applanation tonometry and vice versa. The aim of this study is to determine whether brimonidine has an effect on central corneal thickness.Methods: 30 eyes of patients who attended the Ophthalmology OPD between the time period October 2017 and June 2018 who were newly diagnosed with normal tension glaucoma with no history of any systemic illness or not on any medication were included. Each patient underwent a complete ophthalmic evaluation including fundus examination, visual field assessment, intraocular pressure, central corneal thickness measurement by pachymetry before as well as 1 month and 6 months after starting treatment with 0.2% topical brimonidine twice daily.Results: Administration of brimonidine 0.2% resulted in an increase in central corneal thickness from 525±21 µm before starting brimonidine to 528±21 µm (p<0.05) after 1 month and 535±20 µm (p<0.001) after 6 months. It also resulted in a reduction in intraocular pressure from an initial value of 16±2 mmHg before starting brimonidine to 14±2 mmHg (p<0.05) and 13±2 mmHg (p<0.05), 1month and 6 months after starting treatment, respectively.Conclusions: The data presented in this study show that topical administration of 0.2% brimonidine twice daily results in a significant increase in central corneal thickness in patients with normal tension glaucoma.

Intraocular Pressure Reduction in the Treatment of Normal-Tension Glaucoma

2020 ◽  
pp. 67-72
Author(s):  
Alan D. Penman ◽  
Kimberly W. Crowder ◽  
William M. Watkins
Keyword(s):  
Clinical Trial ◽  
Intraocular Pressure ◽  
Visual Field ◽  
Natural History ◽  
Visual Loss ◽  
Normal Tension Glaucoma ◽  
Pressure Reduction ◽  
Glaucomatous Damage ◽  
Intraocular Pressure Reduction ◽  
History Of

The Collaborative Normal-Tension Glaucoma Study (CNTGS) was a randomized clinical trial to determine the effectiveness of a 30% reduction in intraocular pressure (IOP) (using either medical therapy or filtration surgery) on visual field (VF) progression in eyes with normal-tension glaucoma. The study found that reducing the IOP of patients with normal-tension glaucoma by 30% is beneficial to prevent progression of glaucomatous damage if the visual effects of cataracts are excluded from consideration. However, because not all untreated patients progressed, the natural history of normal-tension glaucoma must be considered before embarking on IOP reduction with therapy that may exacerbate cataract formation, unless normal-tension glaucoma threatens serious visual loss.

scholarly journals Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events

2012 ◽  
pp. 1547 ◽  
Author(s):  
Toyoaki Tsumura ◽  
Hirotaka Suzumura ◽  
Keiji Yoshikawa ◽  
Kimura ◽  
Sasaki ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Adverse Events ◽  
Ophthalmic Solution ◽  
Normal Tension Glaucoma
Sign in / Sign up

Export Citation Format

Share Document